{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:05:33Z","timestamp":1773335133519,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a malignant clonal disease originating from plasma cells. Patients with MM are prone to infections due to factors such as impaired immune function, bone marrow suppression, and anticancer therapy. A systematic review and meta-analysis of risk factors for infections in patients with MM provides evidence-based guidance for clinical risk assessment and intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Search databases such as PubMed, Web of Science, Embase, Cochrane Library, from the establishment of the database to July 20, 2025, to include observational studies evaluating risk factors for infection in patients with MM. Use the NOS tool for literature quality assessment and perform meta-analysis using Stata 15.0 to combine odds ratios (OR) and 95% confidence intervals (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 15 articles (1 case-control study and 14 cohort studies), involving 4,717 participants. The results of this meta-analysis suggest that age &amp;gt; 65 [OR = 1.72, 95% CI (1.18, 2.48)], male [OR = 1.70, 95% CI (1.11, 2.62)], smoking [OR = 2.97, 95% CI (1.94, 4.57)], International Staging System III [OR = 2.22, 95% CI (1.81, 2.73)], diabetes [OR = 2.67, 95% CI (1.74, 4.09)], immunomodulatory drugs [OR = 3.40, 95% CI (2.29, 5.07)], hemoglobin &amp;lt;10 g\/dL[OR = 2.28, 95% CI (1.65, 3.16)], creatinine \u2265 2 mg\/dL[OR = 2.80, 95% CI (2.07, 3.79)] was significantly associated with infection in patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis indicate that age &amp;gt;65 years, male gender, smoking, ISS stage III, diabetes, use of immunosuppressive agents, hemoglobin &amp;lt;10 g\/dL, and creatinine \u22652 mg\/dL are all significant risk factors for infection in MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251065706\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1726340","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:33Z","timestamp":1773293253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for infections in patients with multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiulian","family":"He","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, People\u2019s Hospital of Nanbu County","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Anzhen Nanchong Hospital of Capital Medical University & Nanchong Central Hospital","place":["Nanchong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","article-title":"Targeting GPRC5D for multiple myeloma therapy","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7039","article-title":"Up-front treatment of elderly (Age \u226575 years) and frail patients with multiple myeloma","volume":"22","author":"Abdallah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"103193","DOI":"10.1016\/j.eclinm.2025.103193","article-title":"Global landscape and trends in lifetime risks of haematologic Malignancies in 185 countries: population-based estimates from GLOBOCAN 2022","volume":"83","author":"Sun","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN guidelines\u00ae Insights: multiple myeloma, version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52366","article-title":"Multiple myeloma incidence, mortality, and prevalence estimates and projections, Australia, 1982-2043: a statistical modelling study","volume":"221","author":"Luo","year":"2024","journal-title":"Med J Aust"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01545-2","article-title":"Personalized treatment of multiple myeloma in frail patients","volume":"26","author":"Lipof","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02582-6","article-title":"CAR-T for multiple myeloma: practice pearls","volume":"60","author":"O\u2019Leary","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02396-3","article-title":"Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma","volume":"38","author":"Husby","year":"2024","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287783","article-title":"Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma","author":"Dima","year":"2025","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e14273","DOI":"10.1111\/tid.14273","article-title":"Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual","volume":"26","author":"Yeoh","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"B18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00299-8","article-title":"The global epidemiology of personality disorder: a systematic review and meta-regression","volume":"12","author":"Shadid","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e14439","DOI":"10.1111\/tid.14439","article-title":"Invasive fungal diseases in patients with multiple myeloma: experience at a large, urban referral center","volume":"27","author":"Baneman","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2138380","article-title":"Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma","volume":"64","author":"Bici","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2200068","DOI":"10.1200\/GO.22.00068","article-title":"Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: A multicenter prospective cohort study in latin america","volume":"8","author":"Bove","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12879-016-2155-1","article-title":"Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-1627","article-title":"Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma","volume":"10","author":"Huang","year":"2021","journal-title":"Trans Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"413149","DOI":"10.1155\/2014\/413149","article-title":"The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma","volume":"2014","author":"Jung","year":"2014","journal-title":"BioMed Res Int"},{"key":"B27","article-title":"Analysis on related factors of pulmonary infection in patients with multiple myeloma treated with bortezomib","volume":"29","author":"Li","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195908","article-title":"Risk factors of infection in relapsed\/refractory multiple myeloma patients treated with lenalidomide and dexamethasone (Rd) regimen: real-life results of a large single-center study","volume":"11","author":"Mikulski","year":"2022","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102562","DOI":"10.1016\/j.jiac.2024.11.012","article-title":"Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period","volume":"31","author":"Pan","year":"2025","journal-title":"J Infect Chemother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.09.2362","article-title":"Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay","volume":"46","author":"Riva","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig","year":"2019","journal-title":"Eur J Haematol"},{"key":"B34","article-title":"Clinical characteristics and risk factors of infection in hospitalized patients with multiple myeloma with new generation therapies","volume":"32","author":"Yang","year":"2024","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.10.012","article-title":"Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma","volume":"29","author":"Zhou","year":"2023","journal-title":"J Infect Chemother"},{"key":"B36","doi-asserted-by":"crossref","first-page":"e2025025","DOI":"10.4084\/MJHID.2025.025","article-title":"How first-line therapy is changing in non-transplant eligible multiple myeloma patients","volume":"17","author":"Fazio","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0308463","DOI":"10.1371\/journal.pone.0308463","article-title":"Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis","volume":"19","author":"Mahmud","year":"2024","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701946","article-title":"Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy","volume":"24","author":"Aslan","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.013","article-title":"Special considerations for supportive care and management of complications in elderly patients with multiple myeloma","volume":"21","author":"George","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00301.x","article-title":"Multiple myeloma in elderly patients: presenting features and outcome","volume":"66","author":"Rodon","year":"2001","journal-title":"Eur J Haematol"},{"key":"B41","first-page":"497","article-title":"Diagnosis and treatment of multiple myeloma in Hunan Province","volume":"47","author":"Liu","year":"2022","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1114972","article-title":"Eastern Cooperative Oncology Group, \u03b22-microglobulin, hemoglobin, and lactate dehydrogenase can predict early grade\u2009\u2265\u20093 infection in patients with newly diagnosed multiple myeloma: A real-world multicenter study","volume":"14","author":"Lu","year":"2023","journal-title":"Front Microbiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","article-title":"Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality","volume":"10","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Blood Cancer J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"ofaf127","DOI":"10.1093\/ofid\/ofaf127","article-title":"Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study","volume":"12","author":"Shafat","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179895","article-title":"(11)C-methionine PET\/CT in assessment of multiple myeloma patients: comparison to (18)F-FDG PET\/CT and prognostic value","volume":"23","author":"Morales-Lozano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.022","article-title":"High-dose bendamustine, etoposide, cytarabine, and melphalan (BeEAM) conditioning before autologous transplantation for patients with multiple myeloma","volume":"28","author":"Solomon","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"815013","DOI":"10.5402\/2011\/815013","article-title":"Multiple myeloma and diabetes","volume":"2011","author":"Issa","year":"2011","journal-title":"ISRN Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02125-1","article-title":"Reduced progression of monoclonal gammopathy of undetermined significance to multiple myeloma in type 2 diabetes mellitus: will metformin never stop its pleasant surprises","volume":"39","author":"Papachristou","year":"2022","journal-title":"Adv Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmad104","article-title":"Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin","volume":"55","author":"Jia","year":"2024","journal-title":"Lab Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e82571","DOI":"10.7759\/cureus.82571","article-title":"Analysis of ubiquitin-conjugating enzyme E2T (UBE2T) protein levels in the bone marrow biopsy specimens of patients with multiple myeloma","volume":"17","author":"Wang","year":"2025","journal-title":"Cureus"},{"key":"B54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/ol.2024.14267","article-title":"Clinical implications and predictive value of the creatinine\u2212cystatin C ratio in patients with multiple myeloma and renal impairment","volume":"27","author":"Sun","year":"2024","journal-title":"Oncol Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.01.003","article-title":"Spot urine protein\/creatinine ratio as an alternative to 24-hour urine collection for measuring proteinuria in patients with multiple myeloma: A prospective study","volume":"25","author":"Jamshed","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1726340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:36Z","timestamp":1773293256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1726340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":55,"alternative-id":["10.3389\/fonc.2026.1726340"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1726340","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1726340"}}